-
Mar.292021NEWS
HanAll Biopharma, Restructured to Seung-kook Park and Seung-won Jeong Joint Representative System, Accelerating Advancement as a Global Biopharmaceutical Company
HanAll Biopharma, Restructured to Seung-kook Park and Seung-won Jeong Joint Representative System, A..
-
Mar.122021NEWS
HanAll Biopharma’s Chinese Partner HBM Initiates the First Dosing of Phase 3 in Dry Eye Disease
HanAll Biopharma’s Chinese Partner HBM Initiates the First Dosing of Phase 3 in Dry Eye Disease
-
Feb.082021NEWS
HanAll Biopharma Completes Meeting with FDA for next Phase 3 Trials in Dye Eye Disease
HanAll Biopharma Completes Meeting with FDA for next Phase 3 Trials in Dye Eye Disease
-
Jan.192021NEWS
HanAll Biopharma Net Income for 2020 Increased by 14% Year-on-year to KRW 21.9 Billion
HanAll Biopharma Net Income for 2020 Increased by 14% Year-on-year to KRW 21.9 Billion
-
Nov.192020NEWS
HanAll Biopharma HL036 Clinical Trial Results Selected as Best Poster at AAO 2020
HanAll Biopharma HL036 Clinical Trial Results Selected as Best Poster at AAO 2020
-
Oct.292020NEWS
HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating Income, and Net Profit for the Third Quarter
HanAll Biopharma Recorded KRW 22.1 Billion, KRW 1 Billion, and KRW 3.7 Billion in Sales, Operating I..